Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Fineline Cube Apr 27, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

CSPC Pharmaceutical’s Enronsubaimab Gets NMPA Nod for Recurrent Cervical Cancer

Fineline Cube Jul 1, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company

Reckitt’s New Shanghai R&D Center to Boost Innovation in Health and Hygiene Products

Fineline Cube Jul 1, 2024

Reckitt (LON: RKT), a UK-based manufacturer of consumer health and hygiene products, is planning to...

Company Drug

Johnson & Johnson Achieves Positive Phase III Results for Nipocalimab in Generalized Myasthenia Gravis

Fineline Cube Jul 1, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading US-based healthcare company, has announced positive results...

Company Deals

Hasten Biopharmaceutical Expands into Pan-Asia Regions with Celltrion Asset Acquisition

Fineline Cube Jul 1, 2024

Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an...

Company Drug

Bio-Thera Solutions’ BAT2094 Wins NMPA Nod for Acute Coronary Syndrome Treatment

Fineline Cube Jul 1, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Company Drug

Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge

Fineline Cube Jul 1, 2024

Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking...

Company Drug

Luye Pharma’s Manufacturing Facility Passes FDA Inspection for Paliperidone Palmitate Product

Fineline Cube Jun 28, 2024

Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that it has successfully...

Company Drug

Sirnaomics’ STP707 Shows Promising Results in Phase I Pancreatic Cancer Trial

Fineline Cube Jun 28, 2024

Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company, has announced the successful completion of a Phase...

Company Deals

Shandong Junxiu Biotechnology Partners with Swiss Firm Geistlich to Boost Regenerative Medicine

Fineline Cube Jun 28, 2024

Shandong Junxiu Biotechnology Co., Ltd, a Chinese manufacturer of implantable regenerative medicine devices, has entered...

Company Drug

Genmab and AbbVie’s Epcoritamab Earns FDA Accelerated Approval for Follicular Lymphoma

Fineline Cube Jun 28, 2024

Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, and its co-development partner AbbVie (NYSE: ABBV),...

Company Deals

AbbVie Bolsters Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

Fineline Cube Jun 28, 2024

AbbVie (NYSE: ABBV), a major U.S. pharmaceutical company, has announced the acquisition of Celsius Therapeutics...

Company Drug

Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply

Fineline Cube Jun 28, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious...

Company Deals

Novo Nordisk Moves to Acquire 2seventy bio’s Hemophilia A Program and Gene-Editing Technology

Fineline Cube Jun 28, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading Danish biopharmaceutical company, is transitioning from a...

Company Drug

Hybio Pharmaceutical Gets FDA Nod for Tirzepatide Raw Materials in DMF Filing

Fineline Cube Jun 28, 2024

Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Abbisko Therapeutics Presents Positive Phase II Results for HCC Treatment at ESMO-GI

Fineline Cube Jun 28, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotech company, has announced the presentation of...

Company Deals

China’s Kingfriend Biochemical Acquires U.S.-Listed Adalimumab Biosimilar Yusimry for USD 40 Million

Fineline Cube Jun 28, 2024

Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced the...

Company Deals

Shanghai Kehua Bioengineering’s Subsidiary to Acquire Remaining Stake in Technogenetics S.P.A.

Fineline Cube Jun 28, 2024

Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a Chinese bioengineering company, has announced that its...

Company Drug

Dizal Pharmaceutical’s Golidocitinib Breaks Record with Rapid Market Launch in China

Fineline Cube Jun 28, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has seen its...

Company Deals

GenScript Biotech Receives Over USD 410 Million in Milestone Payments for CAR-T Therapy from Janssen Biotech

Fineline Cube Jun 28, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Deals

Jianke.com, China’s Leading Chronic Disease Management Platform, Files for Hong Kong IPO

Fineline Cube Jun 28, 2024

Jianke.com, a China-based smart healthcare service platform, has filed for an initial public offering (IPO)...

Posts pagination

1 … 329 330 331 … 656

Recent updates

  • NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting
  • Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
  • AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC
  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Others

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.